Login
Xencor Inc logo

Xencor Inc

xencor.com

What Do They Do?

Develops engineered antibody drug candidates and protein technologies for cancer and autoimmune diseases, advancing its own programs and partnering with pharmaceutical and biotechnology companies.

How Do They Make Money?

Partners pay Xencor upfront for licenses, milestone payments when development, regulatory or sales targets are met, and royalties tied to licensed products' sales. Distinct licenses are paid when delivered; milestone and royalty payments depend on reaching milestones or partner sales.

revenue
SegmentShareRevenue
License
Sold outright
0.0%
FY2022: 0.0%
Milestone
Usage-based

36%
FY2022: 3.3%
Royalties
Usage-based

64%
FY2022: 92%
Collaboration
0.0%
FY2022: 4.3%

Who Are Their Customers?

Pharmaceutical and biotechnology partners license Xencor's technologies and drug candidates for development and commercialization; the company also advances selected candidates itself.

Do Revenues Turn Into Profits?

No. It lost $91.9M in FY2025.

Operating income, FY2025
−141% of revenue
▲ +1% (Loss) vs FY2024 (−$178.4M, −161%)
Net income, FY2025
−73% of revenue
▲ +60% (Loss) vs FY2024 (−$232.6M, −211%)
Free cash flow, FY2025
−110% of revenue
▲ +34% (Loss) vs FY2024 (−$208.3M, −189%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +455%
vs $21M in Q3 FY2025
Net income
▲ Turned profitable
vs −$6M in Q3 FY2025
Royalties share of revenue vs 100.0% in Q3 FY2025
  • Jul 29, 2026 Xencor settled its Ultomiris royalty dispute with Alexion It will receive $105 million in two equal payments, and Alexion will make no further U.S. sales royalty payments; ex-U.S. royalties continue.
  • Mar 9, 2026 Genentech elected to terminate its collaboration agreement The agreement covering efbalropendekin alfa, its sole active collaboration product, ends September 4, 2026.

Fewer kinds of candidates The older report described the pipeline as including engineered cytokines as well as bispecific antibodies. The latest report centers its development efforts on antibody candidates, including bispecific formats, and does not describe cytokine candidates as part of its pipeline.

More focused oncology strategy The older report said the company advanced bispecific antibody and cytokine candidates across its portfolio. The latest report says it has prioritized T-cell-engaging bispecific antibody programs in oncology.

Revenue over time
License Milestone Royalties Collaboration Non-cash royalties Non-cash royalties
$500M$250M$0

Who Do They Compete With?

Competes with Amgen, Genmab A/S, Regeneron Pharmaceuticals, Roche Holding, Astellas, Context Therapeutics, CytomX Therapeutics, Immunocore Holdings, Janux Therapeutics, Johnson & Johnson, Rondo Therapeutics, Takeda Pharmaceutical, Third Arc Bio, Vir Biotechnology, Candid Therapeutics, Cullinan Therapeutics, Novartis, Absci, Caldera Therapeutics, and Merck &

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support